Structural heart, for more patients.

The last decade transformed treatment of structural heart disease. Catheter-based valve therapies that once required open-chest surgery are now delivered through the femoral vein, in cases that previously had no option at all.

But a meaningful share of patients screened for these therapies never reach the procedure. Their underlying anatomy disqualifies them on the imaging table. They are sent home on medical management, with limited alternatives and a disease that often gets worse on its own.